Shi et al. (225) reported safety and antitumor activity of GPC3 CAR-T cells in GPC3+ HCC patients, and 11 phase I/II trials are ongoing, including one targeting GPC3/TGFβ (NCT03198546). Here, TGFB1 is linked to hepatocellular carcinoma.